Treatment-Related Adverse Events of Antibody Drug Conjugates Identified
Overall incidence of treatment-related adverse events was 91.2 percent and included lymphopenia, nausea, neutropenia
Diagnosis & Disease Information
Tradipitant Relieves Nausea, Other Gastroparesis Symptoms
Patients taking tradipitant demonstrated significant improvements in nausea compared with placebo.
FDA Approves Aponvie for the Prevention of Postoperative Nausea, Vomiting
Aponvie is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant as a 30-second IV injection.
NDA Submitted for Aprepitant 30-Second IV Injection for Postoperative Nausea, Vomiting
HTX-019 is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant, a substance P/NK1 receptor antagonist, as a 30-second IV injection.
ASA: Dexamethasone Use During Cancer Surgery May Reduce Mortality
Intraoperative administration of dexamethasone linked to reduced 90-day mortality after surgery to remove solid tumors
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Postop Nausea, Vomiting Therapy Barhemsys Launched
Barhemsys is a selective dopamine-2 and dopamine-3 receptor antagonist.
Akynzeo Injection, a New Liquid Formulation, Now Available
Akynzeo is a combination of palonosetron, a 5-HT3 receptor antagonist, and fosnetupitant, a substance P/NK1 receptor antagonist.
Ready-to-Dilute Liquid Formulation of Akynzeo Injection Approved
The FDA has approved a new ready-to-dilute liquid formulation of Akynzeo® injection (fosnetupitant/palonosetron; Helsinn) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, in combination with dexamethasone in adults.
